Connor, Clark & Lunn Investment Management (CC&L)’s Lexicon Pharmaceuticals LXRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-282,467	Closed	-$432K	–	1638
2023 Q4	$432K	Sell	282,467 -54,597	-16%	-$64.9K	﹤0.01%	1085
2023 Q3	$367K	Buy	337,064 +2,813	+0.8%	+$4.94K	﹤0.01%	1095
2023 Q2	$765K	Buy	334,251 +125,918	+60%	+$334K	﹤0.01%	875
2023 Q1	$506K	Buy	208,333 +73,776	+55%	+$169K	﹤0.01%	873
2022 Q4	$257K	Buy	+134,557	New	+$286K	﹤0.01%	1006
2021 Q1	–	Sell	-48,249	Closed	-$165K	–	1041
2020 Q4	$165K	Sell	48,249 -62,014	-56%	-$118K	﹤0.01%	839
2020 Q3	$159K	Buy	110,263 +39,352	+55%	+$70.1K	﹤0.01%	857
2020 Q2	$141K	Buy	70,911 +27,211	+62%	+$53.3K	﹤0.01%	930
2020 Q1	$85K	Buy	+43,700	New	+$130K	﹤0.01%	946
2018 Q1	–	Sell	-40,575	Closed	-$401K	–	765
2017 Q4	$401K	Buy	40,575 +28,000	+223%	+$291K	﹤0.01%	652
2017 Q3	$155K	Buy	+12,575	New	+$186K	﹤0.01%	768

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LXRX Position: Q1 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2024, closing a stake of 282,467 shares — an estimated $432K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LXRX in Q3 2017 and held it in 11 quarters. The position peaked at $765K in Q2 2023. 119 funds tracked by Wall St. Rank hold LXRX as of Q1 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Lexicon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 282,467 Lexicon Pharmaceuticals shares in Q1 2024, an estimated $432K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 11 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Lexicon Pharmaceuticals position peaked at $765K in Q2 2023.
119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2024, filed 9 May 2024.